Angiography, Chronic Musculoskeletal Disease, Computed Tomography, Magnetic Resonance Imaging, Transarterial Embolization
Conditions
Brief summary
Transarterial microembolization (TAME) is a novel treatment option for chronic musculoskeletal pain, especially suitable for patients who have not responded to conservative treatment or are unsuitable for surgical procedures. This minimally invasive technique primarily targets abnormal neovascularization for embolization, relying heavily on precise information provided by various imaging techniques to ensure the effectiveness and safety of the treatment. This study aims to explore the application of integrating preoperative magnetic resonance imaging (MRI) evidence of patient pain and intraoperative high-resolution synchronous imaging information from fused computed tomography (CT) and angiography systems. This integration is intended to enhance preoperative planning, intraoperative guidance, and final treatment outcome assessment, focusing on its crucial contribution to treatment success. It is hoped that this approach will provide pain intervention physicians with reliable diagnostic tools and safe treatment methods, thereby improving treatment outcomes for patients with chronic musculoskeletal pain.
Interventions
PROCEDURETransarterial microembolization (TAME)
TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
Sponsors
Tri-Service General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with chronic musculoskeletal shoulder or knee joint pain in our hospital, including degenerative knee arthritis, adhesive capsulitis of the shoulder, and those confirmed by physical examination or ultrasound-guided injection to have tendinopathy or ligamentopathy, who have failed drug therapy, rehabilitation, or injection treatments, with a duration of symptoms greater than three months, are the target population of this study.
Exclusion criteria
* Pregnancy, coagulation disorders, symptoms of relevant local infections or tumors, and patients allergic to contrast agents. Patients must have complete medical records; those who do not meet the inclusion criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain relief | day 0, day 1, week 1, month 1, month 3, and month 6. | Pain relief is measured according to the Visual Analog Scale (VAS) immediately prior to (baseline) and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional improvement (for shoulder joint) | day 0, day 1, week 1, month 1, month 3, and month 6. | Functional improvement is measured according to Shoulder Pain and Disability Index (SPADI) for patients with chronic shoulder pain immediately prior (baseline) to and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6. |
| Functional improvement (for knee joint) | day 0, day 1, week 1, month 1, month 3, and month 6. | Functional improvement is measured according to the Western Ontario and McMaster Universities Arthritis Index (WOMAC) for patients with chronic knee pain immediately prior (baseline) to and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6. |
Other
| Measure | Time frame | Description |
|---|---|---|
| The technical success rate of TAME procedure | Immediately after the TAME procedure | The technical success rate is judged according to the digital subtraction angiography (DSA). A successful procedure is determined by decreased neovascularization via targeted vessels embolization by the fused CT and angiography system. |
Countries
Taiwan
Contacts
Primary ContactYi-Chih Hsu, M.D.
Outcome results
None listed